ASH 2021 | FLT3 mutation clearance rate in patients with newly diagnosed AML
Eunice Wang
• 13 Dec 2021
In this video, Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares an update on the impact of FLT3 mutation clearance in patients with newly diagnosed acute myeloid leukemia (AML) treated with gilteritinib plus azacitidine or azacitidine monotherapy. As part of the LACEWING trial (NCT02752035), Dr Wang explains that a sensitive next-generation sequencing assay was used to analyze mutation clearance rate in the two patient groups, and reports on the results from this analysis. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
